Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Marc Peeters; Salvatore Siena; Eric Van Cutsem; Alberto Sobrero; Alain Hendlisz; Stefano Cascinu; Haralabos Kalofonos; Giovanna Devercelli; Michael Wolf; Rafael G. Amado

doi:10.1002/cncr.24088

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, Stefano Cascinu, Haralabos Kalofonos, Giovanna Devercelli, Michael Wolf, Rafael G. Amado

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient- reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of pani- tumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorec- tal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed. RESULTS: Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had ≥1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P =.0033). Lower mDLQI scores (

Original language	English
Pages (from-to)	1544-1554
Number of pages	11
Journal	Cancer
Volume	115
Issue number	7
DOIs	https://doi.org/10.1002/cncr.24088
Publication status	Published - Apr 1 2009

Keywords

Colorectal cancer
Health-related quality of life
Panitumumab
Skin toxicity

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/cncr.24088

Cite this

Peeters, M., Siena, S., Van Cutsem, E., Sobrero, A., Hendlisz, A., Cascinu, S., Kalofonos, H., Devercelli, G., Wolf, M., & Amado, R. G. (2009). Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer, 115(7), 1544-1554. https://doi.org/10.1002/cncr.24088

Peeters, M, Siena, S, Van Cutsem, E, Sobrero, A, Hendlisz, A, Cascinu, S, Kalofonos, H, Devercelli, G, Wolf, M & Amado, RG 2009, 'Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy', Cancer, vol. 115, no. 7, pp. 1544-1554. https://doi.org/10.1002/cncr.24088

@article{2ee600a3d33e4156835f96cc8e310fd1,

title = "Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy",

abstract = "BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient- reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of pani- tumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorec- tal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed. RESULTS: Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had ≥1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P =.0033). Lower mDLQI scores (",

keywords = "Colorectal cancer, Health-related quality of life, Panitumumab, Skin toxicity",

author = "Marc Peeters and Salvatore Siena and {Van Cutsem}, Eric and Alberto Sobrero and Alain Hendlisz and Stefano Cascinu and Haralabos Kalofonos and Giovanna Devercelli and Michael Wolf and Amado, {Rafael G.}",

year = "2009",

month = apr,

day = "1",

doi = "10.1002/cncr.24088",

language = "English",

volume = "115",

pages = "1544--1554",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

AU - Peeters, Marc

AU - Siena, Salvatore

AU - Van Cutsem, Eric

AU - Sobrero, Alberto

AU - Hendlisz, Alain

AU - Cascinu, Stefano

AU - Kalofonos, Haralabos

AU - Devercelli, Giovanna

AU - Wolf, Michael

AU - Amado, Rafael G.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient- reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of pani- tumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorec- tal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed. RESULTS: Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had ≥1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P =.0033). Lower mDLQI scores (

AB - BACKGROUND: The authors explored the association of skin toxicity (ST) severity as measured by patient- reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of pani- tumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorec- tal cancer (CRC) trial. METHODS: Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed. RESULTS: Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had ≥1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P =.0033). Lower mDLQI scores (

KW - Colorectal cancer

KW - Health-related quality of life

KW - Panitumumab

KW - Skin toxicity

UR - http://www.scopus.com/inward/record.url?scp=63449142391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449142391&partnerID=8YFLogxK

U2 - 10.1002/cncr.24088

DO - 10.1002/cncr.24088

M3 - Article

C2 - 19189371

AN - SCOPUS:63449142391

SN - 0008-543X

VL - 115

SP - 1544

EP - 1554

JO - Cancer

JF - Cancer

IS - 7

ER -

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this